



Nebraska Medicaid  
Pharmaceutical and Therapeutics Committee Agenda  
**Wednesday, October 29<sup>th</sup>, 2025**

Mahoney State Park, Peter Kiewit Lodge  
28500 West Park Hwy, Ashland, NE 68003

\*A State Park Permit is required

\*A daily parking permit fee of \$7 (NE licensed vehicles) or \$14 (non-NE licensed vehicles) can be purchased at the gate or front desk.

\*Please note meeting will be in-person only. There will not be a virtual attendance option.

**08:00 a.m.** Registration

**09:00 a.m.** Opening of Public Meeting and Call to Order

**\*All Times Below are  
Approximated**

Roll Call

Committee Business

- Conflict of Interest Updates
- Approval of Meeting Minutes: May 14<sup>th</sup>, 2025
- Election of Committee Chair and Vice Chair
- Department Information

**09:15 – 10:15 a.m.** Public Testimony (for Products Recommended to be Non-Preferred)

- [https://nebraska.fhsc.com/Downloads/NE\\_PT\\_PublicTestimony\\_Guidelines.pdf](https://nebraska.fhsc.com/Downloads/NE_PT_PublicTestimony_Guidelines.pdf)
- <http://dhhs.ne.gov/Pages/Pharmacy-Drug-Testimony.aspx>
- Public Testimony Registration Applications will only be accepted by online registration – No faxed/mailed requests will be accepted

**10:15 – 11:15 a.m.** Committee Closed Session – Session to Public Attendees Will Close

**11:15 – 12:00 p.m.** Resume Open Session, Room Re-opens for Public Attendees

- Consideration of Consent Agenda
- Consideration of Therapeutic Class Reviews

**12:00 – 1:00 p.m.** Working Lunch for Committee Members – Closed Session

**1:00 – 5:00 p.m.** Resume Open Session  
Consideration of Therapeutic Class Reviews (Continued)  
Break (if required)  
Adjournment

**Next meeting: Wednesday, May 13<sup>th</sup>, 2026**

**Consent Agenda: (Therapeutic Categories with Unchanged Recommendations)**

The following classes have no changes recommended by the Department and will all be voted on as a group, unless a class is removed from the Consent Agenda.

ANTHELMINTICS	LEUKOTRIENE MODIFIERS
ANTI-ALLERGENS, ORAL	METHOTREXATE
ANTIHISTAMINES, MINIMALLY SEDATING	MOVEMENT DISORDERS
ANTIHYPERTENSIVES, SYMPATHOLYTICS	ONCOLOGY, ORAL - LUNG
ANTIHYPERURICEMICS	ONCOLOGY, ORAL - PROSTATE
ANTIPSORIATICS, ORAL	ONCOLOGY, ORAL - RENAL CELL
ANTIPSORIATICS, TOPICAL	ONCOLOGY, ORAL - SKIN
BRONCHODILATORS, BETA AGONIST	OPHTHALMIC ANTIBIOTICS
COLONY STIMULATING FACTORS	OPHTHALMIC ANTIBIOTIC-STEROID COMBINATIONS
COUGH AND COLD, NARCOTIC	OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS
ENZYME REPLACEMENT, GAUCHERS DISEASE	OPHTHALMICS, ANTI-INFLAMMATORIES
ERYTHROPOIESIS STIMULATING PROTEINS	OTIC ANTIBIOTICS
HISTAMINE II RECEPTOR BLOCKER	OTIC ANTI-INFECTIVES & ANESTHETICS
IDIOPATHIC PULMONARY FIBROSIS	SEDATIVE HYPNOTICS
IMMUNOMODULATORS, ASTHMA	STERIODS, TOPICAL MEDIUM
IMMUNOMODULATORS, TOPICAL	STERIODS, TOPICAL VERY HIGH
INTRANASAL RHINITIS AGENTS	

**Therapeutic Class Reviews: (Therapeutic Categories with New Recommendations)**

ALZHEIMER'S AGENTS	NSAIDS
ANTIPARKINSON'S AGENTS	ONCOLOGY, ORAL - BREAST
ANXIOLYTICS	ONCOLOGY, ORAL - HEMATOLOGIC
BILE SALTS	ONCOLOGY, ORAL - OTHER
COPD AGENTS	OPHTHALMICS, DRY EYE AGENTS
CYTOKINE AND CAM ANTAGONISTS	OPHTHALMICS, GLAUCOMA AGENTS
EPINEPHRINE, SELF-ADMINISTERED	SICKLE CELL ANEMIA TREATMENTS
GLUCOCORTICOIDS, INHALED	STERIODS, TOPICAL HIGH
GLUCOCORTICOIDS, ORAL	STERIODS, TOPICAL LOW
HEMOPHILIA TREATMENT	STIMULANTS AND RELATED AGENTS
IMMUNOMODULATORS, ATOPIC DERMATITIS	THROMBOPOIESIS STIMULATING PROTEINS